# Novo Nordisk CEO Faces Scrutiny Over Ozempic and Wegovy Prices in the US – Congress questions the Novo Nordisk CEO about the pricing of Ozempic and Wegovy in the US. – Concerns raised about the affordability of these weight loss medications for patients. – Novo Nordisk defends the pricing, stating the investments in research and development. Novo Nordisk is facing scrutiny from Congress regarding the pricing of its weight loss medications, Ozempic and Wegovy, in the US. The CEO was questioned about the affordability of these medications for patients, with concerns raised about the high costs. Despite the backlash, Novo Nordisk defended its pricing strategy by highlighting the significant investments in research and development that have gone into developing these drugs. The company remains committed to making these medications accessible to those who need them, while also ensuring the sustainability of their business. ### Hot Take It’s important for pharmaceutical companies like Novo Nordisk to balance the need for affordable medications with the costs of research and development. While pricing can be a sensitive issue, it’s crucial to consider the value that these weight loss medications bring to patients’ lives. Accessibility and affordability should be key considerations moving forward. Weight Loss Disclaimer: Individual results may vary. Always consult with a healthcare provider before starting any weight loss program. Contact Mindful Evolution today for expert guidance on weight loss solutions. Visit our website at https://yourmindfulevolution.com or reach out to us via call or text at 954-639-9960. Remember, we offer telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.